The primary objective of this systematic review was to assess the effectiveness of SGLT2 inhibitors in the management of heart failure, with a particular emphasis on cardiovascular outcomes, hospitalization rates, and quality of life. The gene discussed is SLC5A2; the disease is heart failure.